# RAS(ON) tri-complex inhibitors

Source: https://onco.cc/technologies/ras-on-tri-complex-inhibitors/  
OnCo record `ras-on-tri-complex-inhibitors` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Drugs that block RAS, the growth switch stuck on in many cancers, by an indirect route. The drug first attaches to cyclophilin A, a common protein inside cells, and the pair then clamps onto RAS while it is switched on, so RAS can no longer pass its signal along. Daraxonrasib, approved in the United States in 2026 for pancreatic cancer, works this way; others are in trials.

## Summary

The first KRAS drugs, sotorasib and adagrasib, bind the inactive state of one mutant, G12C. The active, GTP-bound state of RAS has no pocket for a conventional small molecule. Tri-complex inhibitors reach it with help from a second protein: Schulze and colleagues (Science 2023) designed a natural-product-inspired molecule that remodels the surface of cyclophilin A to create a new interface with high affinity and selectivity for active KRAS G12C, and the three-part complex of cyclophilin A, drug and KRAS shut down oncogenic signalling and regressed tumours in several human cancer models.

The same approach has given three kinds of drug, all from Revolution Medicines. Multi-selective, non-covalent inhibitors bind the active state of mutant and wild-type KRAS, NRAS and HRAS: the tool compound RMC-7977 (Holderfield, Nature 2024) and daraxonrasib, RMC-6236 (Jiang, Cancer Discovery 2024; Cregg, J Med Chem 2025), an orally available macrocycle that sits in a composite pocket formed by cyclophilin A and the switch I and switch II regions of RAS. Elironrasib (RMC-6291) is a covalent inhibitor selective for active KRAS G12C. Zoldonrasib (RMC-9805) is covalent and selective for G12D, where the cyclophilin A interface speeds the reaction between the mutant aspartate and a warhead of very low intrinsic reactivity (Weller, Science 2025).

Daraxonrasib is the member with a randomised trial and an approval: in RASolute 302 it lengthened median survival in previously treated metastatic pancreatic cancer to 13.2 months against 6.7 with chemotherapy, and the FDA approved it on 26 August 2026. Its label describes the mechanism in the same terms: binding to cyclophilin A gives a binary complex that binds active RAS, and the tri-complex blocks interactions with downstream effectors and promotes GTP hydrolysis. Zoldonrasib and elironrasib are in clinical trials and have no approval.

## Fields

- Kind: Technology
- Status: approved
- Last checked: 2026-11-18
- Also known as: Tri-complex inhibitors; Tricomplex inhibitors; RAS(ON) inhibitors; RAS-GTP inhibitors; Cyclophilin A tri-complex inhibitors
- Principle: The inhibitor binds cyclophilin A; the resulting binary complex binds the active, GTP-bound state of RAS, and the three-part complex blocks RAS from engaging its downstream effectors.
- Since: 2026
- Strengths: Reaches the active state of RAS, which has no pocket for a conventional small molecule; One approach has produced a multi-selective inhibitor and mutant-selective covalent inhibitors for G12C and G12D; In preclinical models a multi-selective inhibitor stopped the growth of KRAS G12C cancers that had become resistant to G12C inhibitors through restored RAS signalling (Holderfield 2024); Daraxonrasib lengthened survival over chemotherapy in a randomised phase 3 trial in pancreatic cancer
- Limitations: Multi-selective members also inhibit wild-type KRAS, NRAS and HRAS; with daraxonrasib in RASolute 302, rash (87%), diarrhoea (67%) and stomatitis (56%) were the most common adverse reactions; The drugs work through cyclophilin A: the daraxonrasib label says to avoid systemic cyclosporine A, which binds the same protein; The molecules are large macrocycles beyond the usual rule-of-five limits for oral drugs (Cregg 2025); Of the members held here, only daraxonrasib has a reported randomised trial and an approval

## Sources

- Schulze et al., Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS (Science 2023): https://doi.org/10.1126/science.adg9652
- Holderfield et al., Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy (Nature 2024): https://doi.org/10.1038/s41586-024-07205-6
- Jiang et al., Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 (Cancer Discovery 2024): https://doi.org/10.1158/2159-8290.CD-24-0027
- Cregg et al., Discovery of daraxonrasib (RMC-6236) (J Med Chem 2025): https://doi.org/10.1021/acs.jmedchem.4c02314
- Cregg et al., Discovery of elironrasib (RMC-6291) (J Med Chem 2025): https://doi.org/10.1021/acs.jmedchem.4c02313
- Weller et al., A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors (Science 2025): https://doi.org/10.1126/science.ads0239
- O'Reilly et al., Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer, RASolute 302 (N Engl J Med 2026): https://doi.org/10.1056/NEJMoa2605555
- FDA prescribing information for Rasonque (daraxonrasib): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/)
- trials: [RASolute 302](https://onco.cc/trials/rasolute-302/)
- key papers: [Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy](https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/), [Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer](https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/)

---
JSON: https://onco.cc/api/v1/entities/ras-on-tri-complex-inhibitors.json